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Updating the role of matrix 
metalloproteinases in mineralized 
tissue and related diseases
Bone development and healing processes involve a complex cascade 
of biological events requiring well-orchestrated synergism with bone cells, 
growth factors, and other trophic signaling molecules and cellular structures. 
Beyond health processes, MMPs play several key roles in the installation of 
heart and blood vessel related diseases and cancer, ranging from accelerating 
metastatic cells to ectopic vascular mineralization by smooth muscle cells 
in complementary manner. The tissue inhibitors of MMPs (TIMPs) have an 
important role in controlling proteolysis. Paired with the post-transcriptional 
efficiency of specific miRNAs, they modulate MMP performance. If druggable, 
these molecules are suggested to be a platform for development of “smart” 
medications and further clinical trials. Thus, considering the pleiotropic effect 
of MMPs on mammals, the purpose of this review is to update the role of those 
multifaceted proteases in mineralized tissues in health, such as bone, and 
pathophysiological disorders, such as ectopic vascular calcification and cancer.
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Introduction
Bone is a specialized, vascular, and dynamic 
connective tissue in constant remodeling to maintain 
physiological ion homeostasis, give support and 
protection for soft tissue, and be a reservoir of ions 
important to vertebrates.1-3 Mechanistically, bone 
remodeling requires a coordinate and dynamic 
relationship between deposition/degradation of 
extracellular matrix (ECM), through growth factors 
and other signaling molecules, which results in 
ECM remodeling—an important prerequisite for cell 
adhesion, migration, proliferation, differentiation.4 It 
is well known that osteoclasts resorb the mineralized 
matrix and further promote the remodeling of the 
organic fraction of the bone, while, conversely, 
osteoblasts are responsible for bone formation by 
depositing specialized ECM components prior to 
mineralizing it properly2. The balance between those 
specialized cells is crucial for maintaining appropriate 
bone mass, and the lack of this synchronism 
contributes to the occurrence of bone diseases, such 
as osteoporosis and Paget’s. To date, ultimate bone 
cellular differentiation is known to depend on well-
orchestrated communication between formation and 
resorption events.2,5-7
More specifically, during bone repair after trauma, 
bone healing depends on interactions between specific 
signaling inflammatory cytokines and non-resident and 
eventual cells (such as polymorphonuclear leukocytes 
and monocyte-macrophage lineage),8 requiring ECM 
remodeling by specific matrix metalloproteinases 
(MMPs). Generally, MMPs are an important family of 
zinc-dependent endopeptidases and are the major 
class of enzymes responsible for the degradation or 
resorption of all ECM components (Figure 1).9-15 MMP 
targets include other proteases, protease inhibitors, 
blood coagulation factors, chemotactic molecules, 
latent growth factors, binding protein growth factor, 
cell surface receptors, and cell adhesion molecules.16-19 
At this stage, bone remodeling is necessary for 
the homeostasis of systemic calcium release, bone 
turnover, and repair/regeneration of injured bone.20
In turn, MMPs are important regulators of 
the cellular and physiological processes affecting 
crucial biological processes, such as angiogenesis, 
morphogenesis, tissue repair, and are decisive tools 
for the occurrence of some diseases, such as cancer, 
cardiovascular disorders, arthritis, among others.21-23 
Particularly, MMP-2 plays a role in bone embryonic 
development, tissue repair, and tumorigenesis,24 while 
MMP-7 stimulates bone differentiation and extracellular 
matrix degradation,25 and MMP-9 seems to be involved 
in osteoclast-based bone remodeling.25,26 Generally, 
MMPs are secreted in latent form, such as pro-enzymes 
or zymogens, and therefore require proteolytic 
activation occurring after the precise removal of the 
inhibitory pro-peptide. This biochemical processing 
occurs by breaking the link between the cysteine-
containing thiol group and the zinc in the catalytic 
domain27,28, resulting in an optimal conformational 
structure for exerting catalysis mechanisms. MMPs 
are classified respecting their structure and/or 
their specific substrates, resulting in a family of 25 
members actually (Figure 2).18,29 Conversely, TIMPs 
are responsible for controlling the breakdown of 
ECM components by negatively modulating MMPs 
and they are involved in a range of important 
biological phenomena and pathological events such 
as inflammation and tumor invasion. It is known that 
the TIMPs range of activities can be even wider if we 
consider their effect on the inhibition of several ADMs 
and ADMTSs (disintegrins and metalloproteinases).19,30 
Additionally, the human genome encodes four genes 
for TIMPs (TIMP-1 to 4) and have approximately 
40% of conserved sequences among them. More 
specifically, TIMP-2 and TIMP-4 have the most similar 
sequences with 50% similarity.19,30 The structure of the 
N-terminal region is highly conserved in all TIMPs that 
can bend as a separate unit performing its function in 
inhibiting MMPs.18,31
Because of the classic role of TIMPs, which control 
extracellular matrix proteolysis (ECM) through the 
endogenous inhibition of MMPs, it is suggested that 
increased TIMP results in either accumulation of 
ECM or fibrosis, while the decrease in TIMP leads to 
an intense matrix proteolysis.32 Thus, ideal tissue 
remodeling requires a balance between MMPs and 
TIMPs. The inhibitory activity of TIMPs may be 
important in inhibiting malignant tumor progression 
leading to invasion and metastasis.33 Regardless of 
inhibition of MMP, TIMPs act as signaling molecules 
with cytokine-like activities, thus influencing various 
biological processes, including cell growth, apoptosis, 
differentiation, angiogenesis, and oncogenesis.34
Bone remodeling and repair comprehend an 
extraordinarily complex sequential mechanism 
requiring dynamic and intense ECM components 
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breakdown and drive cell fates involved with adhesion, 
proliferation, differentiation mechanisms, such as well 
as releasing signaling active molecules during the 
remodeling process of the hematoma tissue. In this 
scenario, MMPs are particularly important members 
controlling this mechanism and their regulation is 
decisive to adequate bone healing. Because MMPs 
participate in almost all phases of bone repair, they 
are important biomarkers of this very complex 
and coordinated process.16,35 To the best of our 
MMPs TIMPs References
MMP-1 TIMP-4 Radomski, et al.9 (2002) 
MMP-2 TIMP-2; TIMP-3; TIMP-4 Chowdhury, et al.10 (2015); Suomela, et al.11 (2001); Radomski, et al.⁹ (2002) 
MMP-7 TIMP-1; TIMP-4 Bourboulia & Stetler-Stevenson12 (2010); Radomski, et al.9 (2002) 
MMP-8 TIMP-1 Hästbacka, et al.13 (2015)
MMP-9 TIMP-1; TIMP-3; TIMP-4 Mittal, et al.14 (2016); Suomela, et al.11 (2001); Radomski, et al.⁹ (2002)
MMP-12 TIMP-1 Suomela, et al.11 (2001) 
MMP-13 TIMP-3 Suomela, et al.11 (2001)
MMP-14 TIMP-2; TIMP-4 Itoh15 (2015); Radomski, et al.9 (2002)
Figure 1- List of major MMPs involved in bone repair processes and their tissue inhibitors (TIMP)9-15
Enzyme Classification Substrate
MMP-1 Collagenase Collagens I, II, III, VII, VIII, X, and XI, gelatin, entactin, tenascin, aggrecan, fibronectin, 
vitronectin, myelin basic protein, ovostatin, casein, MMP-2, MMP-9, proMMP-2, proMMP-9
MMP-8 Collagenase Collagen I, II, and III, fibronectin, PGs, aggrecan, ovostatin
MMP-13 Collagenase Collagens I, II, III, IV, IX, X and XIV, gelatin, tenascin, plasminogen, osteonectin, fibronectin, 
aggrecan, casein
MMP-18 Collagenase Collagen, gelatin
MMP-2 Gelatinase Collagen I, III, IV, V, VII and X, gelatin, fibronectin, laminin, aggrecan, elastin, vitronectin, 
tenascin, myelin basic protein
MMP-3 Stromelysins Collagen III, IV, V, IX, X and XI, gelatin, aggrecan, elastin, fibronectin, vitronectin, laminin, 
entactin, tenascin, decorin, myelin basic protein, ovostatin, casein, osteonectin, proMMP-1, 
proMMP-3, proMMP-8, proMMP-9
MMP-9 Gelatinase Collagen IV, V, XI, elastin, aggrecan, decorin, laminin, entactin, myelin basic protein, casein
MMP-10 Stromelysins Collagens III, IV and V, gelatin, elastin, fibronectin, aggrecan, casein
MMP-11 Stromelysins Gelatin, fibronectin, collagen IV, laminin, elastin, casein, PGs
MMP-27 Stromelysins Gelatin
MMP-7 Matrylisin Collagens I and IV, gelatin, elastin fibronectin, vitronectin, laminin, entactin, tenascin, aggrecan, 
myelin, proMMP-1, proMMP-2, proMMP-9 transferrin, casein
MMP-26 Matrylisin Collagen IV, gelatin, fibronectin, fibrinogen, pro-MMP9
MMP-14 MT-MMP (membrane type) Collagen I, II and III, gelatin, fibronectin, tenascin, vitronectin, laminin, entactin, aggrecan, 
vibronectin, pro-MMP2
MMP-15 MT-MMP (membrane type) Fibronectin, tenascin, entactin, laminin, aggrecan, gelatin, vibronectin, pro-MMP2
MMP-16 MT-MMP (membrane type) Collagen III, gelatin, fibronectin, casein, laminin, pro MMP-2
MMP-17 MT-MMP (membrane type) Gelatin, fibrinogen, pro MMP-2
MMP-24 MT-MMP (membrane type) Fibronectin, gelatin, proteoglycans, pro-MMP2
MMP-25 MT-MMP (membrane type) Collagen IV, gelatin, fibronectin, proteoglycans, pro-MMP2
MMP-12 Other Enzymes Collagens I, V and IV, gelatin, elastin, fibronectin, vitronectin, laminin, entactin, osteonectin, 
aggrecan, myelin, vitronectin, fibrinogen
MMP-19 Other Enzymes Collagen I and IV, gelatin, lamin, entactin, fibronectin, aggrecan.
MMP-20 Other Enzymes Amelogenin, aggrecan.
MMP-21 Other Enzymes N.D.
MMP-23 Other Enzymes Gelatin
MMP-28 Other Enzymes Casein
Source: Adapted from Visse and Nagase18 (2003) and Bonnans, Chou and Werb29 (2014)
Figure 2- List of MMPs, according their classification and substrate18,29
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knowledge, this review updates the role of these 
endopeptidases in mineralized tissue and their effect 
on pathophysiological conditions (Figure 3).21-23,36-46
MMPs are important mediators of bone 
physiology
Bone tissue is a very dynamic tissue and requires a 
repertoire of enzymes capable of degrading the organic 
fraction of the bone matrix, thus, the action of MMPs 
and their inhibitors have physiological relevance. The 
absence of some molecules, such as MMP-9, MT1-MMP 
(MMP-14), or MMP-13 during the skeletal development 
results in severe abnormalities in the bone growth 
plate of long bones, impairing normal bone formation. 
The ECM remodeling requires specific activities of 
MMPs. The literature reports an increase in MMPs 2, 
-3, -9, -13, in osteoblast that leads to bone resorption 
by stimulating interleukin-1 and - 6.4,24
The role of each MMP involved in bone remodeling 
is not fully clear, but it is known that MMP-2, -13, 
and -14 plays an essential role. In fact, due to the 
proteolytic activity of the bone matrix, regulation 
bioavailability of soluble RANKL, cell–cell interaction, 
coupled with bone resorption to bone formation, 
intercellular communication in bone cells, and cell–
ECM interaction occurs.20 According to Mizutani, et 
al.4 (2001), MT1-MMP actives MMP-2, cleaving the 
pro-peptide latent form, and MMPs 2; -3; -9; -13, 
and MT-MMPs play an important role in both formation 
and bone resorption (Figure 4).4,20,24,47 In addition, our 
group has shown a molecular mechanism involved 
in osteoblast differentiation in vitro, requiring the 
expression of MMP-9, with higher expression on the 
28th day.3 Furthermore, this study showed that both 
MMP -2 and -9 were regulated during osteoblast 
differentiation and apparently TIMP-2 was essential in 
the late osteoblast maturation. As seen, recent studies 
highlight the important involvement of proteases in the 
extracellular matrix solubilization process, their role 
in determining where and when the reabsorption will 
start, and its relationship with new bone formation. 
However, little is known about the molecular details 
involved in such process, which makes research in 
this field focused on the discovery and identification 
of proteinases.47
In addition to TIMPs, another endogenous MMP 
inhibitor was discovered recently: RECK (“reversion-
inducing cysteine-rich protein with Kazal motifs”).48 
RECK is a membrane-anchored glycoprotein capable 
of negatively regulating peri-cellularly MMPs and 
compromises ECM remodeling, triggering signaling 
pathways, such as Notch, which is essential for the 
process of angiogenesis.3,49 Because of this, RECK has 
been considered a prognostic marker and potential 
therapeutic macromolecule in solid cancers. However, 
although some progress has been achieved highlighting 
the role of RECK in cancer, our knowledge on their 
role in bone is scarce. Updating the literature in this 
regard, Accorsi-Mendonca, et al.47 (2008) evaluated 
the expression of matrix metalloproteinase-2, -9 
and RECK through immunohistochemistry during the 
well-characterized alveolar bone regeneration model: 
their results show that active and/or inactive forms 
of MMP-2 and MMP-9, and RECK are differentially 
expressed by osteogenic cells and connective tissue 
such as bone formation, maturation, and remodeling. 
Also concerning craniofacial structures, Demarchi, 
et al.50 (2010) showed differential, temporal, and 
Figure 3- Matrix metalloproteinases are involved in several biological mechanisms, mainly in bone repair and regeneration, which occurs 
during the homeostasis of MMPs when the osteoclast performs their role in reabsorption and the osteoblast forms a new matrix. In contrast, 
the MMPs act in pathological conditions such as progression of tumor, bone diseases as OA or RA and ectopic cardiovascular calcification. 
Pathophysiological conditions have been observed showing that the action of EVs and miRNAs had implicated in the regulation of MMPs 
acting in others functions in the organism21-23,36-46
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spatial expression of RECK during the development of 
secondary palate. This distribution was compared with 
the expression of MMP-2, MMP-3, and MMP-9, and they 
suggested RECK might reorganize the epithelium and 
mesenchyme palatine blades. Additionally, we have 
also dedicated to evaluate the involvement of MMPs 
and their inhibitors in adaptive osteoblast processes 
to biomaterials, and it is clear that ECM remodeling is 
a prerequisite to drive cell adhesion on biomaterials 
surfaces.51-55
Although bone healing is a physiological mechanism 
able to regenerate enough tissue to heal small injuries, 
larger lesions require therapeutic alternatives to 
support bone growth. In this context, bone tissue 
engineering emerges as an interesting field within 
regenerative medicine, providing strategies to 
regenerate lost bone and thereafter restoring their 
physiological function.3 In this aspect, the cooperation 
of biology, chemistry, physic, engineering, and 
biomedicine is established to evaluate biomaterials 
serving as scaffold for bone growth. The studies 
have focused on classifying metallic, organic, and 
inorganic materials regarding international rules of 
biocompatibility. Thus, we have tested the hypothesis 
that MMP-9 may be involved in tissue remodeling 
in response to xenogeneic hydroxyapatite, due to 
MMP-9 role in the breakdown of extracellular matrix 
components. The presence of CD68+ cells in response 
to natural hydroxyapatite was also investigated. The 
results suggest that tissue remodeling in response to 
natural hydroxyapatites requires MMP-9 expression 
and CD68+ cell recruitment.3 This was also extended 
to the MMP2 role in reactive tissue in response to 
granules of hydroxyapatite.56 To date, CD68 is a 
macromolecule widely found in macrophages and 
here they were discussed to drive osteoclastogenesis.3
Thus, it is essential the balance between 
metalloproteinases and their inhibitors to understand 
the mechanisms involved in bone ECM remodeling and 
keep bone quality. If certain MMPs are not expressed 
during bone formation, the process does not take place 
accordingly, e.g.: inflammatory conditions, human 
genetic mutations, metabolic disorders, bone tumors, 
and metastasis.20
A sophisticate manner to release MMPs: 
extracellular vesicles
Over the last years, it has been proposed that MMPs 
are released by using the sophisticate extracellular 
vesicles (EVs) strategy. EVs are nano- and micro-sized 
membrane-bound vesicles such as exosomes and 
microvesicles, secreted by many types of cells that 
can transport cargo, including proteins, lipids, nucleic 
acids, and membrane receptors from donor cells.36,57,58 
Figure 4- Osteoblast cells release MMPs (as -2, -3, -9 and -13), which have an important role in bone metabolism, activating osteoclast 
cells and consequently initiating matrix degradation. Afterwards, several matrix metalloproteinases work in coordination in order to form 
new ECM. Thus, a new mineralized matrix is formed through regulatory mechanism of cells and MMPs4,20,24,47
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It has also been observed that EVs share structures 
homologous to those with matrix vesicles (MVs), 
which are characteristic of matrix mineralization, such 
as mineralization of cartilage, bone and dentin, for 
example.36 EVs are released by plasma membranes, 
differentiating chondrocytes growth, odontoblasts, 
and osteoblasts.36,59 In general, these MVs contain 
matrix processing enzymes, such as MMP-2, MMP-9 
and MMP-13, which play an important role in matrix 
remodeling, mainly degradation of proteoglycans, 
and allow calcification.60,61 Additionally, the activation 
of TGF-β takes place through MVs containing MMP-3, 
synthetized by growth plate-resident chondrocytes 
and the production of matrix vesicles is induced by 
phosphate through extracellular signal-regulated 
kinases ERK1/2 pathway.36 Until now, MVs and EVs 
exhibit similar activities for mineralization of ECM, but 
are biological distinct entities.62
The secretion and high number of EVs into 
biological fluids represent an exceptionally large 
interactive surface area that establishes contact 
with cells and molecules in the extracellular micro-
environment.63 Therefore, the presence of matrix 
processing enzymes in EVs and their secretion along 
the entire cell periphery provides an additional layer 
of interactome and play an active role in pathological 
and physiological processes.36 According to Liu, et al.64 
(2018), bone-remodeling micro-environment, bone-
derived EVs contains specific osteogenic proteins, 
such as bone morphogenetic protein 1-7, alkaline 
phosphatase (ALP), eukaryotic initiation factor 2, 
and noncollagenous matrix proteins, such as bone 
sialoprotein, osteopontin, osteocalcin, and osteonectin. 
Moreover, EVs contain matrix-degrading enzymes such 
as MMPs, heparanases, hyaluronidases, extracellular 
matrix metalloproteinase inducer (EMMPRIN), 
aggrecanases, such as adamalysin metalloproteinases 
having disintegrin and thrombospondin domains 
(ADAMTSs), and TIMPs, among others.36 Altogether, 
these findings led us to reinforce the role of these 
microvesicles in delivering MMPs at the outside 
compartment. This process seems to be essential in 
the signaling of molecules proteolytically involved 
with mineralization mechanism. EVs are a biological 
strategy to deliver ECM-related proteases.
In fact, for their conversion into functionally 
active MMPs, membrane-type MMPs are internalized 
to the endosomes and are recycled to the plasma 
membrane.65 However, instead of recycling, the 
membrane-like proteins of the endosomes might be 
cleaved, converted into functionally active soluble 
forms, and packaged in the intraluminal vesicles and 
secreted via EVs,66 e.g.: after MMP14 internalization in 
the endosomes, this molecule was not recycled back 
into the plasma membrane, but rather packed into 
EVs and secreted into the extracellular environment 
to act as a functionally active soluble.67 Lastly, the 
detection of these secreted molecules in circulating 
EVs of various body fluids makes them an ideal source 
of disease biomarkers.68,69
The understanding of how extracellular vesicles act 
in intercellular communication as paracrine mediators 
in normal conditions as well as cause the progression 
of diseases has aroused interest of researchers. Cells 
are known to use cytoplasmic extensions that act 
as open-ended channels called tunneling nanotubes 
(TNTs) to connect cells at a long distance and make 
the exchange of cytoplasmic material easy. Thus, in the 
future, EV and TNTs should be used as  drug-delivered 
vector against many diseases.70
The other side of the coin: role of MMPs in 
tissue disorders
Cancer
Signals coming from the outside at the surrounding 
micro-environment, such as growth factors, 
extracellular matrix (ECM), adjacent stromal cells, 
cytokines, and chemokines, profoundly influence 
stem cell fates.71 The complete understanding of the 
extracellular matrix remodeling is crucial to deliver 
signals guiding cellular phenotypes and, as expected, 
MMPs are discussed as important proteases in this 
context. In conjunction, MMPs play several key roles 
in the metastasis mechanism and might contribute to 
all stages of tumor progression and implantation.71,72
Molecularly, there are more than 500 genes 
encoding proteases or protein-like proteases in the 
human genome.73 However, among all proteolytic 
enzymes potentially associated with tumor invasion, 
members of the MMP family have emerged as important 
proteases mainly because of their ability to degrade 
almost all components of the ECM and basement 
membrane, allowing cancer cells to penetrate, infiltrate 
in the underlying stromal matrix,74,75 and initiate 
the metastasis mechanism as well. The process of 
invasion and metastasis of tumor cells occurs basically 
through mechanisms of cellular mobility accompanied 
by degradation of the basement membrane and 
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components of the extracellular matrix.71 MMPs, 
especially MMP-2 and MMP-9 (both known as 
gelatinases A and B, respectively), are involved in 
several mechanisms contributing to cell adhesion 
and invasion, and further tumor progression.39,40,76 
The action of proteases assures the breakdown of 
barriers of ECM matrix components, mainly collagen, 
laminins, and proteoglycans, and favors cell invasion, 
thus driving the pathway to orchestrate invasive 
cancer cells.71 In conjunction, MMPs are able to 
guide adherent cell phenotype by interfering on cell 
adhesion, also resulting in an adaptive process of 
cancer cells by interacting either with each other or 
with the components of the substrate, reinforcing 
the cell-cell and matrix-cell interfaces, respectively.72 
Lastly, MMPs also modify substrates other than 
ECM structural molecules. MMPs activate proteinase 
activated receptors (PARs) by the cleavage of their 
extracellular domains, promoting tumor progression 
and favoring the invasive phenotype. Altogether, 
growth factor-related receptors, cell adhesion 
molecules, chemokines, cytokines, apoptotic ligands, 
and angiogenic factors are just few examples of the 
diversity of substrates recognized by MMPs.74,75
In health, MMP-2 (gelatinase A) is involved in 
many physiological factors and processes, including 
healing and repair as discussed earlier here. However, 
in tumor tissues such as osteosarcoma, the MMP-
2 gene is overexpressed and contributes to the 
acceleration of extracellular components turnover 
and breakdown. Overall, MMP expression plays a 
crucial role in the development of osteosarcoma and 
consequently developing pulmonary metastasis in 
many individuals.39,40 In this way, Zhang & Zhang40 
(2015) found MMP-2 involvement was higher in the 
individuals presenting osteosarcoma than in the 
control group. Moreover, the overall survival rate was 
higher in individuals with negative MMP-2 expression, 
and the group presenting negative expression of 
MMP-2 lived longer than the group with those positive 
expressions. In addition, they show that abnormal 
expression of MMP-2 was associated with pulmonary 
metastasis. Fang, et al.77 (2000) found many other 
roles of MMP-2 in tumor progression, such as their 
involvement with EGFR signaling and integrin, which 
leads to cell migration and the shift to an angiogenic 
phenotype. Thus, it is clear that MMP develops a 
pleiotropic effect on tumor installation by remodeling 
ECM and activating signaling molecules, impacting cell 
adhesion and metastatic phenotype (Figure 5).78-93
Studies suggested that MMPs are involved in 
initial step of ECM degradation during metastatic 
process.5,22,40,72 MMPs have a complex role and 
mediated degradation of ECM components might 
generate inhibitors of angiogenesis, promoting 
stimulate cell migration and/or invasion, and release 
activated cytokines stored in ECM. Type I collagen 
comprises 90% of the organic matrix, in bone matrix 
(BM) and in cancer dissemination, the BM must be 
broken down mainly in interstitial collagenase, MMP-
1.94
Okuyama, et al.94 (2008) suggest that MMP-1 play 
an important role in maintaining high bone metastatic 
potential in their study. Moreover, researchers reported 
that osteoclasts stimulated by cancer cells, directly or 
not, play an important role in bone resorption and in 
breast cancer condition, PTH-rP (parathyroid hormone-
related protein) released by cancer cells stimulate 
the formation and resorptive activity of osteoclasts. 
Prostate cancer shows a tendency to involve bone 
and a marked response of the bone to the presence 
of bone cells, and there is a general consensus that 
bone formation and bone breakdown are present 
within metastatic deposits.95
Nemeth, et al.95 (2002) report that bone is the most 
frequent organ affected and the presence of metastatic 
cells leads to an increase in bone matrix turnover. 
They propose that stimulation of bone matrix turnover 
by metastatic cells may be responsible for a prostate 
cancer tendency towards growing up within the bone 
environment. The MMPs appear to play critical roles in 
prostate cancer metastasis and bone matrix turnover, 
it is hypothesized that inhibition of MMP activity may 
disrupt the cycle of bone matrix turnover and tumor 
cell growth94,95. The communication between tumor 
cells and bone cells increase bone metabolism, and 
the release of stimulatory substances during bone 
matrix turnover enhances growth of cancer cells that 
have colonized bone.95
MiRNAs (miRs)-based post-transcriptional 
processing of MMP and cancer development
The miRs encompasses approximately 17–25 
nucleotides in length and are small endogenous non-
protein coding RNAs whose function is involved in the 
regulation of post-transcriptional gene via translational 
repression or the degradation of their mRNA 
targets.37,38 In summary, most mammalian miRNAs 
use a second mechanism of gene regulation that does 
TOKUHARA CK, SANTESSO MR, OLIVEIRA GS, VENTURA TM, DOYAMA JT, ZAMBUZZI WF, OLIVEIRA RC
J Appl Oral Sci. 2019;27:e201805968/14
not involve the cleavage of their mRNA targets. miRs 
exert their regulatory effects by binding to imperfect 
complementary sites within the 3′ untranslated regions 
(UTRs) of their mRNA targets and they suppress 
target-gene expression post-transcriptionally at the 
level of translation by means of a RISC complex that is 
similar, or possibly identical to the one that is used for 
the RNAi pathway.96 The activities of miRs are essential 
for gene regulation during skeletal development 
and homeostasis, and their adequate expression 
is essential for bone formation and maintenance. 
Furthermore, miRs regulates signaling pathways 
such as TGFβ, BMP, and Wnt that are involved with 
dynamics and bone disorders, emphasizing their 
potential therapeutic role.97 Thus, miRs involved in 
bone pathologies such as osteosarcoma and cancer 
metastasis pose as interesting targets for possible 
intervention.98 However, the in vivo functions of 
individual miRNAs in maintaining bone homeostasis 
and resulting in disease, clinical applications, and 
expression need to be better addressed.99
Since MMPs develop crucial roles in several 
physiological processes in health and disorders, it is 
urgent to comprehend their molecular mechanism, 
such as those promoted by miRs-based mechanism 
to molecular processing MMPs. The miRs are 
involved in multiple functions, such as proliferation, 
apoptosis, senescence and differentiation, playing an 
indispensable role in tumor initiation/progression, 
metastasis, invasion in many types of cancer, and the 
post-transcriptional regulation of MMPs is modulated by 
miRs100-103 (Figure 5). Additionally, polymorphisms are 
MiRNAs MMPs Effect Disease Reference
miR-203 MMP-1 Increased expression of miR-203 leads to a considerable 
increase in MMP-1 levels in rheumatoid arthritis synovial.
Rheumatoid
arthritis synovial
Stanczyk, et al.78 (2011)
miR-539 MMP-8 MMP-8 is a direct target of miR-539, plays a key role in 
inhibiting cell invasion and migration.
Osteosarcoma Jin, et al.79 (2015)




Akhtar, et al.80 (2010)
miR-143 MMP-13 MMP-13 is the direct target of miR-143, promoting cellular 
invasion.
Osteosarcoma Osaki, et al.81 (2008)
miR-29b MMP-2 MMP-2 is identified to be a miR-29b target and regulates 
cell growth.
Prostate cancer Steele, et al.82 (2010)
miR-206 MMP-2 MiR-206 downregulates MMP-2, this regulation results in the 
suppression of cell invasion and migration.
Breast cancer Steele, et al.82 (2010)
miR-885-5p/
miR-491-5p
MMP-9 MiR-885-5p and miR-491-5p demonstrate to reduce levels 
of MMP-9 expression and inhibit cellular invasion.
Glioma Yan, et al.83 (2011)
miR-155 MMP-3 MMP-3 is directly repressed by the exogenous expression of 




Stanczyk, et al.84 (2008)
miR-492 MMP-10 MiR-492 plays a vital role in pelvic lymph node metastasis 
via regulating miR-492/TIMP2/MMP10 axis.
Pelvic lymph node
metastasis (LNM)
Liu, et al.85 (2018)
miR-125a-
5p
MMP-11 Overexpression of miR-125a-5p results in inhibition of 
osteosarcoma cell migration and invasion by targeting 
MMP-1.
Osteosarcoma Waresijiang, et al.86 
(2016)
miR-148a MMP-7 MMP-7 is a direct and functional target of miR-148a. MiR-
148a plays a significant role in GC invasion by regulating 
MMP7 expression.
Gastric cancer Sakamoto, et al.87 (2014)
miR-337-3p MMP-14 MiR-337-3p suppress MMP-14 expression, inhibiting growth, 
invasion, metastasis, and angiogenesis. 
Gastric cancer Xiang, et al.88 (2015)
miR-146b MMP-16 MiR-146b inhibits MMP-16 and cause a significantly 
suppress invasion and cell motility.
Glioblastoma Xia, et al.89 (2009)
miR-29b MMP-24 MiR-29b inhibits the expression of MMP-24 which mediates 
an anticancer effect.
Glioblastoma Shin, et al.90 (2017)
miR-134b MMP-12 Overexpression of miR-134b inhibits expression of MMP-12 
and suppress tumor growth.
Glioma Liu, et al.91 (2017)
miR-193b-
3p
MMP-19 MiR-193b-3p is an important regulator of MMP-19 in human 
chondrocytes and may relieve the inflammatory response in 
OA.
Osteoarthritis Chang, et al.92 (2018)
miRNA144 MMP-28 MMP-28 is downregulated by miRNA144, involved in 
mechanism of tumor proliferation and migration. 
Colorectal cancer Xiao, et al.93 (2015)
Figure 5- Summary of the miRNAs effect over MMPs in some diseases78-93
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also important in genes encoding MMPs and they lead 
to changes in MMP expression patterns in cancer.104 
The relations between the MMP overproduction in 
tumor or stromal cells and the progression of cancer 
led to the development of clinical trials testing a series 
of inhibitors intended to block the proteolytic activity 
of these enzymes. However, the application of MMP 
inhibitors in patients was unsuccessful because some 
MMPs may play a paradoxical protective role in tumor 
progression along with the identification of new roles 
of MMPs in the initial stages of cancer.74,75
MMPs and specific inflammatory landscape
MMPs have been listed in many disorders. In 
rheumatoid arthritis (RA) and osteoarthritis (OA), 
the MMP’s activities are directly related to cartilage 
degradation. According to Xue, et al.105 (2014), 
endogenous MMP-2 or MMP-9 collaborate to survival, 
proliferation, migration, and invasion of RA synovial 
fibroblast. In addition, MMP-9 stimulates RA synovial 
fibroblast-mediated inflammation and degradation 
of cartilage, contributing to joint destruction. The 
overproduction of MMP-13 by chondrocytes during 
onset and in progression of OA, promoting the 
extracellular matrix degradation.43,44
In the study by Zeng, et al.45 (2015), protein 
levels of MMP-1, MMP-2 and MMP-9 were higher in 
patients with OA compared to the control group, 
and the ethnicity showed that levels of MMP-1 and 
MMP-2 were higher in Asians with OA compared to 
the control group. However, the levels of MMP-9 in 
OA patients were higher than that of control group, 
Asians and Caucasians.45 Additionally, the matrix 
metalloproteinases are responsible for collagen and 
ECM degradation, in periodontal disease.106 MMP-8 
and MMP-13 related to tissue destruction followed 
with significant contribution of MMP-9 and MMP-14.46
MMPs and ectopic vascular calcification
As above-mentioned, mineralization is not an 
exclusive mechanism of bone. more specifically, 
ectopic vascular calcification has become an important 
topic in public health and over the last years, several 
studies have shown the important involvement of 
MMPs and TIMPs in cardiovascular diseases, including 
coronary artery disease,107 myocardial infarction,108 
atherosclerosis,109 and ischemic stroke.110,111 In 
cardiovascular diseases, MMPs act in the weakening of 
vessels since they are able to degrade all their major 
components, essential for the maintenance of vascular 
tonus.112 The main MMPs involved in cardiovascular 
diseases are MMP-2 and MMP-9.41,42
We have shown recently that the mechanostimulation 
of smooth muscle cells provokes hypermethylation of 
the TIMP1 promotor, resulting in a decrease of TIMP1 
transcription and translation in conjunction with an 
increased matrix remodeling enzymatic activity. 
Therefore, we have defined a novel-signaling pathway 
responsible for the physiological adaptation of vessel 
smooth muscle to changes in mechanical pressure, 
which are potentially relevant for defining novel 
avenues for the rational treatment of diseases.113 
Chemical-motivated inhibitors of MMPs have been 
shown to be promising strategies for cardio-protection. 
Bencsik, et al.114 (2014) found that the inhibitor of 
MMP ilomastat was able to moderately inhibit the 
expression of MMP-2 in rats with induced myocardial 
infarction, which led to the conclusion that its function 
is sufficient to confer cardiovascular protection. A 
physiological imbalance between MMPs and TIMPs may 
also result in disorders involving the heart and blood 
vessels.91,109 On the other hand, MMP inducers appear 
to contribute with the progression of cardiovascular 
diseases. EMMPRIN, one of these inducers, has been 
implicated in the development of vascular diseases, 
including the pathogenesis of myocardial infarction.108 
Understanding the role of MMPs and their endogenous 
or synthetic inhibitors in the cardiovascular system 
may contribute to the modulation of these factors in 
the case of heart disease115 and vascular disorders such 
as vascular calcification, which is an important etiology 
for disturbance of the blood flow reaching high blood 
flow pressure locally and systemically. Of course, the 
calcification process requires a dynamic remodeling of 
ECM prior to the deposition of inorganic components, 
and there has been discussion on whether this process 
repeats osteogenic features or not 4,20,35,47.
MMP inhibitors as an alternative for anti-cancer 
therapy
Considering the importance of MMPs roles in 
modulating ECM rearrangement and consequently 
affecting cell viability, the knowledge about their 
molecular processing is urgent. Many MMP inhibitors 
have been designed and synthesized seeking to treat 
malignant tumors or other disorders, which requires 
intense ECM remodeling in order to provide changeable 
scaffold during the adhesion and migration stages. 
Among these drugs, peptidomimetics, non-peptide, 
tetracycline derivatives and bisphosphonates can 
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interfere in MMP activities and they are expected to 
modulate cancer progression. Thus, the function of 
MMP inhibitors has been sought as an alternative form 
of anticancer therapy.116
The literature is controversial regarding the use of 
several synthetic types of MMP inhibitors. The study 
by Santos, et al.117 (1997) evaluated the action of 
some MMP inhibitor-related compounds (AG3287, 
AG3293, AG3294, AG3296, AG3319 and AG3340), 
using lung carcinoma as experimental model, and 
found that AG3340 was the most effective in inhibiting 
neoplastic growth. However, other compounds, such 
as AG3293 and AG3294, did not present anti-tumor 
action. The selectivity of those inhibitors must also 
be considered: high selectivity of individual MMPs 
has major biomedical importance. It is known that 
both MMP-2 and MMP-9 are important therapeutic 
targets.118,119 Jha, et al.118/EndNote> (2016) evaluated 
the mechanism of inhibition of epigallocatechin-
3-gallate (EGCG)-mediated MMP-2. Additionally, 
they concluded that the EGCG targets fibronectin II 
repeating regions 1 and 3 of MMP-2, binds the amino 
acids that constitute the exosite of this enzyme and 
hinders the proper positioning of the substrate. 
EGCG is an important polyphenol of green tea with a 
potential chemotherapeutic agent demonstrating anti-
metastatic and MMP inhibitory activities in addition to 
various other already known biological activities.118,120 
Additionally, the effects of EGCG were also evaluated 
in anti-proliferation and anti-migration against bladder 
cancer SW780 cells for both in vitro and in vivo. 
Treatment of EGCG resulted in significant inhibition 
of cell proliferation by induction of apoptosis, with 
no toxicity to cells of the normal bladder epithelium. 
When tested in vivo, EGCG significantly decreased 
tumor volume in mice with SW780 tumors (tumor 
weight decreased 68.4%). In addition, it regulated the 
expression of nuclear factor kappaB (NF-kB) and MMP-
9 at both protein and mRNA levels in tumor cells and 
SW780. EGCG was shown to be effective in inhibiting 
the proliferation and migration of SW780 cells and 
inhibited SW780 tumor growth by down-regulation of 
NF-κB and MMP-9.120
Inhibition of MMP does not only intend to be used 
in cancer therapy but also in other diseases. In a 
recent study, a new mercaptosulfonamide-based MMP 
inhibitor, YHJ-7-52, was evaluated in the differentiation 
of human mesenchymal stem cells (hMSCs) into 
adipocytes and in the accumulation of lipids. The 
YHJ-7-52 was shown to be an effective regulator of 
hMSC adipogenesis. Inhibition of MMP was also able to 
suppress lipid accumulation in adipocytes co-treated 
with Troglitazone. These authors suggest that MMP 
inhibitors might be used as molecular tools for research 
on adipogenesis and treatment of obesity. Therefore, 
inhibition of MMP not only provides cancer therapy, but 
also a great potential for adipogenesis and treatment 
of obesity.121
Wylie, et al.122 (1999) found that Batimastat (BB-
94) is a MMP inhibitor and Maekawa, et al.123 (2000) 
evaluated the action of MMI-166, an inhibitor with 
selective spectrum for gelatinases, on several models 
of metastasis. They found that this drug significantly 
reduced growth of tumor metastasis in the lung, liver, 
and peritoneal cavity in vivo, although it does not affect 
neoplastic cell growth in vitro, reinforcing the limitation 
of these in vitro models to some anti-tumor studies. 
Thebiology of MMPs is thus very complex and has been 
listed within several pathologies, and as such further 
studies are necessary evaluating these proteases as 
promising therapeutic strategies.116 However, it is 
important to note that further investigation is urgent 
for determining the clinical efficacy and safety of these 
many suggested synthetic MMP inhibitors in humans.
Thus, to the best of our knowledge, the understanding 
of MMPs biology at a physiological, cellular, and 
molecular level should drive pharmacological studies 
focusing on the chemical inhibition of pathological 
processes. Therefore, new strategies to better 
elucidate these mechanisms are necessary, by 
complementing advancements in the structural and 
biochemical understanding of MMPs biology within 
mineralized tissues and this update on understanding 
their role in the body claims for preclinical analysis and 
further clinical trials.
Conclusion
MMPs are widely distributed in physiological 
processes and in conjunction they drive important 
biological mechanisms such as angiogenesis, 
embryogenesis and dynamic tissue remodeling 
throughout growth and aging. However, the main role 
of MMPs is shared with important etiology of diseases, 
such as bone and vascular disorders and cancer. Thus, 
the understanding of the biology of MMPs should be 
considered chemical routes to synthetize drugs capable 
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to efficiently and selectively affect MMP activities. This 
review updated the knowledge on the importance of 
MMPs and their inhibitors in distinguishing health and 
diseases conditions, reporting the modulation of their 
molecular processing and activities and reinforcing the 
need to use their biochemical mechanism lessons as 
templates for the chemical development of new drugs 
aiming for mostly efficient therapies.  
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